Charles E. van Horn

Charles E. van Horn is an experienced patent litigation attorney, currently serving as Of Counsel at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. His practice primarily focuses on intellectual property matters, including patents and patent prosecution. His technical expertise spans chemical and biotechnology patents, as evidenced by his involvement in securing a patent term extension for Otsuka Pharmaceutical Co., Ltd.'s drug REXULTI® (brexpiprazole). He was recognized for his intellectual property work in the 2017 LMG Life Sciences Rankings.

In his tracked appearances, Mr. Van Horn has exclusively represented defendants. His sole tracked case is Cyberfone Systems, LLC v. Capital One Financial Corporation, where he defended Capital One Financial Corporation, suggesting experience with technology-related disputes, potentially involving software or financial technology.

Mr. Van Horn was admitted to practice in Virginia in 1968 and in the District of Columbia in 1998, and is registered to practice before the U.S. Patent and Trademark Office. He earned his J.D. from American University Washington College of Law in 1968, an M.B.A. from George Washington University in 1973, and a B.S. from Lehigh University in 1963. His professional background indicates a strong foundation in both legal and technical aspects of intellectual property. Information regarding his specific experience with PTAB or IPR proceedings was not readily available in the public records searched.